Hi Bright Boy. Thanks for answering one of my questions so well. We will be in a good place if we become a royalty company and I can see our royalties growing as we conduct clinical trials for other tumors and also for DCVax Direct. I’ve also wondered if any company could generically match what NWBO has once our patents run out. Our product has multiple stages: leukopherisis has to extract the DC at the optimum time, then the DCs have to be matured properly with the right stimulants, but just as important is how it is then manufactured quickly and recently the use of Flaskworks to make it a commercial success. Our product is nothing like getting hold of a pill by BP and analyzing it for the ingredients. I suspect it will be a difficult product to creat generic equivalents.
Market Data 
Markets 
AI
